Compounds > perillartine
Page last updated: 2024-11-11

perillartine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

perillartine: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5365782
CHEMBL ID21404
MeSH IDM0082835

Synonyms (64)

Synonym
(ne)-n-[(4-prop-1-en-2-ylcyclohexen-1-yl)methylidene]hydroxylamine
1-cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-, oxime, (e)-
perillartine
peryllartine
ai3-52127
einecs 250-402-7
1-cyclohexene-1-carboxaldehyde, 4-isopropenyl-, anti-oxime
l-perillaldehyde alpha-syn-oxime
(e)-4-(1-methylvinyl)cyclohexene-1-carbaldehyde oxime
perilla sugar
1-perillaldehyde alpha-antioxime
4-isopropenyl-1-cyclohexene-1-carboxaldehyde, anti-oxime
1-cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-, oxime
30950-27-7
nsc-1179
nsc1179
perillaldehyde, oxime
4-(1-methylethenyl)-1-cyclohexen-1-carboxyaldehyde oxime
138-91-0
30674-09-0
nsc151796
nsc-151796
CHEMBL21404
AKOS006281261
1-cyclohexene-1-carboxaldehyde, 4-isopropenyl-, oxime
4-(1-methylethenyl)-1-cyclohexene-1-carboxaldehyde oxime (e)
nsc 1179
4-isopropenylcyclohex-1-enecarbaldehyde oxime
einecs 205-344-7
46s302515i ,
unii-46s302515i
1-cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-, oxime, (c(e))-
S9006
(e)-4-(prop-1-en-2-yl)cyclohex-1-enecarbaldehyde oxime
1-perillaldehyde .alpha.-antioxime
l-perillaldehyde .alpha.-syn-oxime
4-isopropenyl-1-cyclohexene-1-carbaldehyde oxime #
XCOJIVIDDFTHGB-YRNVUSSQSA-N
perillaldehyde oxime [mi]
1-cyclohexene-1-carboxaldehyde, 4-isopropenyl-, oxime, (e)-
4-(1-methylethenyl)-1-cyclohexene-1-carbaldehyde (e)-oxime
4-isopropenyl-1-cyclohexene-1-carbaldehyde (e)-oxime
perillartine, (+/-)-
dl-perillartine
(e)-n-hydroxy-1-(4-isopropenyl-1-cyclohexen-1-yl)methanimine
(+/-)-perillartine
(ne)-n-((4-prop-1-en-2-ylcyclohexen-1-yl)methylidene)hydroxylamine
j55.440e ,
W-106923
CS-7666
(e)-n-{[4-(prop-1-en-2-yl)cyclohex-1-en-1-yl]methylidene}hydroxylamine
mfcd00019421
1-perillaldehyde a-antioxime
1-perillaldehyde alpha -antioxime
l-perillaldehyde alpha -syn-oxime
4-isopropenyl-1-cyclohexene-1-carbaldehyde oxime
HY-N2084
DS-4806
DTXSID701014887
CCG-266320
4-(prop-1-en-2-yl)cyclohex-1-enecarbaldehyde oxime
A876061
1-cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-, oxime, [c(e)]-
AC-35083

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID233323Activity expressed by taste potency (taste intensity relative to sucrose on a mole/mole basis)1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Structure--taste relationship of perillartine and nitro- and cyanoaniline derivatives.
AID235433Taste was determined; sweet1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
A consideration for structure-taste correlations of perillartines using pattern-recognition techniques.
AID233344Taste quality1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Structure--taste relationship of perillartine and nitro- and cyanoaniline derivatives.
AID23465Calculated partition coefficient (clogP)1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Structure--taste relationship of perillartine and nitro- and cyanoaniline derivatives.
AID26794Partition coefficient (logP)1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
A consideration for structure-taste correlations of perillartines using pattern-recognition techniques.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (44.44)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.42 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		1.9810clonidine;
imidazoline
3-nitroaniline
3-nitroaniline: used as a sole source of nitrogen , carbon and energy		1.9510
5-nitro-2-toluidine
5-nitro-2-toluidine: structure given in first source; RN given refers to parent cpd. 5-nitro-o-toluidine : A C-nitro compound in which the nitro compound is meta to the amino group and para to the methyl group of o-toluidine.		1.9510C-nitro compound
5-nitro-2-methoxyaniline
5-nitro-2-methoxyaniline: RN given refers to parent cpd		1.95104-nitroanisoles;
substituted aniline
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		2.1310aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
acetoxime
[no description available]		1.9710ketoxime
2-amino-4-nitrophenol
[no description available]		1.95104-nitrophenols
acetaldehyde oxime
acetaldehyde oxime: structure. (E)-acetaldehyde oxime : The (E)-stereoisomer of acetaldehyde oxime.. acetaldehyde oxime : An aldoxime derived from acetaldehyde.		1.9710acetaldehyde oxime
ConditionIndicatedRelationship StrengthStudiesTrials
Lipid Metabolism Disorders
Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body.		02.4110
Fatty Liver, Nonalcoholic
[description not available]		02.610
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		02.610